Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Rössner

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
Lancet (London, England)|April 20, 2005
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe studyLuc F Van Gaal, Aila M Rissanen, André J Scheen, et al.
BMJ (Clinical Research Ed.)|June 3, 2011
Longer term effects of very low energy diet on obstructive sleep apnoea in cohort derived from randomised controlled trial: prospective observational follow-up studyKari Johansson, Erik Hemmingsson, Richard Harlid, et al.
BMJ (Clinical Research Ed.)|December 5, 2009
Effect of a very low energy diet on moderate and severe obstructive sleep apnoea in obese men: a randomised controlled trialKari Johansson, Martin Neovius, Ylva Trolle Lagerros, et al.
European Heart Journal|April 18, 2008
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe StudyLuc F Van Gaal, André J Scheen, Aila M Rissanen, et al.
Diabetes Care|December 29, 2006
Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled studyBjørn Richelsen, Serena Tonstad, Stephan Rössner, et al.
Peerj|July 10, 2015
Influence of rimonabant treatment on peripheral blood mononuclear cells; flow cytometry analysis and gene expression profilingStefan Almestrand, Xiao Wang, Åsa Jeppsson-Ahlberg, et al.
The American Journal of Clinical Nutrition|February 14, 2006
Upward weight percentile crossing in infancy and early childhood independently predicts fat mass in young adults: the Stockholm Weight Development Study (SWEDES)Ulf Ekelund, Ken Ong, Yvonné Linné, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2006
Association of weight gain in infancy and early childhood with metabolic risk in young adultsUlf Ekelund, Ken K Ong, Yvonné Linné, et al.
Eclinicalmedicine|July 11, 2026
Effect of engineered mesoporous silica particles with tailored pore size on glycaemic control in individuals with prediabetes or type 2 diabetes: a randomised, double-blind, placebo-controlled SHINE trialJeanha Baek, Anna Ioannidou, Melissa L Borg, et al.
Circulation|November 3, 2004
Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group I: worldwide demographics of obesityDavid A York, Stephan Rössner, Ian Caterson, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
Lancet (London, England)|April 20, 2005
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe studyLuc F Van Gaal, Aila M Rissanen, André J Scheen, et al.
BMJ (Clinical Research Ed.)|June 3, 2011
Longer term effects of very low energy diet on obstructive sleep apnoea in cohort derived from randomised controlled trial: prospective observational follow-up studyKari Johansson, Erik Hemmingsson, Richard Harlid, et al.
BMJ (Clinical Research Ed.)|December 5, 2009
Effect of a very low energy diet on moderate and severe obstructive sleep apnoea in obese men: a randomised controlled trialKari Johansson, Martin Neovius, Ylva Trolle Lagerros, et al.
European Heart Journal|April 18, 2008
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe StudyLuc F Van Gaal, André J Scheen, Aila M Rissanen, et al.
Diabetes Care|December 29, 2006
Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled studyBjørn Richelsen, Serena Tonstad, Stephan Rössner, et al.
Peerj|July 10, 2015
Influence of rimonabant treatment on peripheral blood mononuclear cells; flow cytometry analysis and gene expression profilingStefan Almestrand, Xiao Wang, Åsa Jeppsson-Ahlberg, et al.
The American Journal of Clinical Nutrition|February 14, 2006
Upward weight percentile crossing in infancy and early childhood independently predicts fat mass in young adults: the Stockholm Weight Development Study (SWEDES)Ulf Ekelund, Ken Ong, Yvonné Linné, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2006
Association of weight gain in infancy and early childhood with metabolic risk in young adultsUlf Ekelund, Ken K Ong, Yvonné Linné, et al.
Eclinicalmedicine|July 11, 2026
Effect of engineered mesoporous silica particles with tailored pore size on glycaemic control in individuals with prediabetes or type 2 diabetes: a randomised, double-blind, placebo-controlled SHINE trialJeanha Baek, Anna Ioannidou, Melissa L Borg, et al.
Circulation|November 3, 2004
Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group I: worldwide demographics of obesityDavid A York, Stephan Rössner, Ian Caterson, et al.
Pageof 15